DRD vs NGVT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DRD exhibits exceptional fundamental health, highlighted by a strong Piotroski F-Score of 8/9 and a pristine balance sheet with zero debt. While the stock trades at a premium to its Graham Number ($16.31), it remains significantly undervalued relative to its intrinsic value ($46.32) and analyst target price ($46.50). High profitability margins and an impressive ROE of 34.71% suggest a highly efficient operation. Despite a bearish technical trend and weak insider sentiment, the underlying financial strength and growth trajectory provide a compelling bullish case.
NGVT exhibits severe fundamental distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 41.84. Despite a 131% increase in share price over the last year, the company's core financials are deteriorating with negative ROE (-133.66%) and shrinking revenue (-14.60%). There is a massive divergence between the bullish price action and the catastrophic balance sheet, suggesting the current valuation is speculative rather than data-driven.
Compare Another Pair
Related Comparisons
DRD vs NGVT: Head-to-Head Comparison
This page compares DRDGOLD Limited (DRD) and Ingevity Corporation (NGVT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.